查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1875881

全球GMP细胞库服务市场

GMP Cell Banking Services
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球GMP细胞库服务市场预计2030年将达22亿美元

全球GMP细胞库服务市场规模在2024年估计为9.394亿美元，预计到2030年将达到22亿美元，在分析期（2024-2030年）内复合年增长率（CAGR）为15.0%。本报告分析的细分市场之一「生物製药公司」预计将以14.6%的复合年增长率成长，并在分析期间结束时达到15亿美元。同时，「契约製造组织」细分市场预计在分析期间内将以16.0%的复合年增长率成长。

美国市场规模估计为2.606亿美元，而中国市场预计将以14.0%的复合年增长率成长。

预计到2024年，美国符合GMP标准的细胞库服务市场规模将达到2.606亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到3.282亿美元，在2024年至2030年的分析期内，复合年增长率（CAGR）将达到14.0%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期内，这两个国家的复合年增长率将分别达到13.0%和12.8%。在欧洲，德国预计将以约10.7%的复合年增长率成长。

全球GMP细胞库服务市场—关键趋势与驱动因素概述

为什么符合GMP标准的细胞库服务在生物製药开发和治疗中变得越来越重要？

由于生物製药行业对安全、可靠、高品质的细胞株的需求日益增长，GMP细胞库服务正变得至关重要。那么，为什么这些服务在今天如此重要呢？ GMP（良好生产规范）细胞库是指在严格的监管和品管标准下建立、保存和维护细胞株。这些服务确保用于生产生物製药、疫苗、基因疗法和其他治疗药物的细胞株不受污染，并能长期保持其完整性。

细胞株在生物製药研发中发挥着至关重要的作用，尤其是在单株抗体、重组蛋白和基因治疗病毒载体的生产方面。符合GMP标准的细胞库建立流程包括建立主细胞库（MCB）和工作细胞库（WCB），这对于生物製药的规模化生产至关重要。细胞株在受控条件下储存，以维持其活性和遗传稳定性，从而确保多个生产批次的一致性。鑑于FDA和EMA等监管机构的要求，GMP细胞库对于满足合规标准、确保治疗药物的安全性和有效性以及加快产品上市速度至关重要。随着生物製药产业随着生物製药和个人化医疗的兴起而不断发展，GMP细胞库服务已成为安全可靠生产这些先进治疗方法的关键组成部分。

科技进步如何提升GMP细胞库服务？

技术创新在提升GMP细胞库服务的效率、安全性和扩充性方面发挥了关键作用，使生物製药公司能够更轻鬆地维持用于治疗药物生产的高品质细胞株。其中一项最具影响力的进展是自动化细胞培养系统的引入，该系统能够实现更精确、更可重复的细胞库建构过程。自动化减少了人为误差，并最大限度地降低了污染风险和细胞株特性变异性，因为细胞库的製备、监测和维护均在最佳条件下进行。这在大规模生产环境中尤其重要，因为在这些环境中，一致性至关重要。

冷冻保存技术的进步使得细胞株的长期保存成为可能，且不会损害细胞的活性或功能。改良的冷冻保护剂配方和冷冻通讯协定提高了在超低温下保存细胞的能力，并降低了冰晶形成的风险，从而避免了冰晶对细胞的损伤。这些进步使得细胞库能够在长期（通常长达数十年）内保持细胞活性，同时保持其遗传和表型的完整性。这对于生物製造工艺的可重复性至关重要，尤其是在需要多年稳定供应高品质细胞的情况下。

将先进的分析和品管技术整合到GMP细胞库中，正在彻底改变这一领域。诸如次世代定序（NGS）、流式细胞技术和数位PCR（dPCR）等技术正被用于更全面地表征细胞株，确保其不含霉浆菌和病毒等污染物，并维持其遗传特性。这些先进的分析技术能够对细胞库品质进行更严格的监控，为生物製药公司提供关于其细胞株健康状况和稳定性的详细资讯。这种程度的控制对于基因疗法和细胞疗法等先进治疗方法的开发尤其重要，因为即使细胞株存在细微的差异，也可能影响最终产品的疗效和安全性。

此外，文件和资料管理系统的进步正在提升GMP细胞库服务的可追溯性和合规性。现代软体平台能够对所有细胞库流程进行全面记录，涵盖从初始表征到冷冻保存和储存的各个环节。这些系统使生物製药公司能够轻鬆追踪其细胞库的历史记录，确保符合监管指南，并方便FDA和EMA等机构的审核。对细胞株进行完全控制和可追溯性验证的能力，对于获得生物製药的监管核准以及确保治疗产品的长期成功至关重要。

为什么GMP细胞库服务对于确保生物製药的安全性、稳定性和可扩展性至关重要？

GMP细胞库服务对于确保生物製药的安全性、稳定性和可扩展性至关重要，因为它们提供了一个可控且合规的系统，用于生产一致的高品质治疗产品。在单株抗体、疫苗和基因疗法等生物製药的生产过程中，细胞株係被用作生物工厂来生产这些复杂的分子。确保这些细胞株无污染、遗传稳定且具有可重复的性能，对于生物製药的成功开发和生产至关重要。

在生物製药产业，安全是重中之重，而符合GMP标准的细胞库服务对于降低细胞株污染和变异性的风险至关重要。细菌、病毒和霉浆菌等污染物会损害生物製药的安全性和有效性，导致不良患者后果和监管召回。 GMP细胞库确保细胞株在用于生产治疗产品之前经过彻底的检测和检验，不含污染物。这种严格的检测和监控流程降低了污染风险，确保生物製药公司能够为患者生产安全可靠的生物製药产品。

稳定性是GMP细胞库的另一个关键优势。生物製药必须长期稳定生产，通常需要多个生产批次，以满足临床试验和商业化的需求。建立主细胞库（MCB）和工作细胞库（WCB）可确保生产中使用的细胞株在遗传上保持稳定，功能上长期可靠。透过冷冻保存主细胞库并以此为基础建立工作细胞库，生物製药公司即使在细胞株最初建立数年后，也能维持其生产流程的一致性。这种稳定性对于维持生物製药在其整个生命週期内的品质和疗效至关重要。

对于商业生物製药生产而言，可扩展性至关重要，因为大规模生产治疗药物的能力是满足市场需求的必要条件。 GMP细胞库服务透过提供稳定、可扩展的高品质细胞株，协助生物製药的大规模生产。生物製药公司利用主细胞库建立工作细胞库，从而获得充足的细胞供应，这些细胞可以放大生产规模，用于任何规模的生产。这种扩充性在基因疗法和细胞疗法等先进治疗方法的开发中尤其重要，因为在这些疗法中，能够以稳定的批次生产大量细胞是商业性成功的关键。

此外，符合GMP标准的细胞库服务透过遵循严格的品管和文件记录标准，帮助生物製药公司满足监管要求。生物製药公司在将生物製药推向市场之前，必须向监管机构证明其细胞株安全、稳定且特性明确。符合GMP标准的细胞库提供满足这些监管要求所需的文件和可追溯性，确保生物製药公司能够有效率地完成核准流程。如果没有符合GMP标准的细胞库，将难以达到监管机构设定的严格标准，进而危及生物製药的研发和商业化。

哪些因素正在推动符合GMP标准的细胞库服务市场的成长？

推动GMP细胞库服务市场成长的关键因素包括：对生物製药和先进治疗方法的需求不断增长、个人化医疗的兴起、全球临床试验的扩展以及生物製药开发监管环境的日益严格。首先，对生物製药（例如单株抗体、疫苗和基因疗法）的需求不断增长是GMP细胞库市场的主要驱动力。随着生物製药公司拓展产品线并纳入更多生物製药，对可靠且合规的细胞库服务的需求也日益增长，以支持这些复杂治疗药物的生产。细胞库对于确保生物製药在研发、临床试验和商业化生产过程中的一致性和品质至关重要。

其次，个人化医疗的兴起推动了对GMP细胞库服务的需求。个人化疗法，例如CAR-T细胞疗法和基因编辑疗法，通常需要使用患者特异性或基因工程改造的细胞株。 GMP细胞库服务在维持这些细胞株的品质和安全性方面发挥着至关重要的作用，确保其在个人化疗法中保持稳定状态。随着生物製药产业不断向个人化医疗转型，对高品质GMP细胞库以支持患者特异性生物製药生产的需求只会不断增长。

全球临床试验的扩展也是推动GMP细胞库市场成长的因素之一。随着临床试验日益国际化并覆盖更广泛的患者群体，生物製药公司必须扩大产能以满足不断增长的治疗产品需求。 GMP细胞库服务提供必要的基础设施，能够大规模生产稳定、高品质的生物製药，确保临床试验不会因供不应求或品质问题而中断。此外，随着更多先进治疗方法进入临床试验阶段，对特性明确、符合GMP规范的细胞库的需求也日益重要。

生物製药研发领域严格的监管环境也推动了对符合GMP标准的细胞库服务的需求。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构要求生物製药公司证明其用于生物製药生产的细胞株符合严格的品质标准。符合GMP标准的细胞库确保这些细胞株经过全面测试、记录完整併符合监管指南，从而降低核准流程延误的风险。随着生物製药监管要求的日益复杂，预计对符合GMP标准的细胞库服务的需求将进一步增长。

总之，GMP细胞库服务市场的成长主要受以下因素驱动：生物製药和先进治疗方法需求的不断增长、个人化医疗的兴起、全球临床试验的扩展以及生物製药开发监管环境的日益严格。随着生物製药产业的不断发展，并日益重视高品质、安全有效的治疗药物的生产，GMP细胞库服务将在支持这些救命治疗方法的开发和商业化方面发挥核心作用。

部分：

细胞类型（哺乳动物、微生物、酵母、昆虫、禽类、其他细胞类型），最终用途（生物製药公司、契约製造组织）

受访公司范例

  • Austrianova Singapore Pte Ltd.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • Goodwin Biotechnology, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Paragon Bioservices, Inc.
  • SGS India Pvt. Ltd.
  • ViruSure GmbH
  • WuXi AppTec

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，革新市场和竞争情报分析。

Market Glass, Inc. 并没有采用查询LLM 或产业专用的SLM 的常见做法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括影片文字稿、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在国、製造地以及进出口（成品和OEM产品）情况，预测企业竞争格局的变化。这种复杂多变的市场现实将对竞争对手产生多方面的影响，包括销货成本增加、盈利下降和供应链重组，同时也会影响微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 世界其他地区

第四章 竞赛

简介目录
Product Code: MCP12206

Global GMP Cell Banking Services Market to Reach US$2.2 Billion by 2030

The global market for GMP Cell Banking Services estimated at US$939.4 Million in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Biopharmaceutical Companies End-Use, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Contract Manufacturing Organizations End-Use segment is estimated at 16.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$260.6 Million While China is Forecast to Grow at 14.0% CAGR

The GMP Cell Banking Services market in the U.S. is estimated at US$260.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$328.2 Million by the year 2030 trailing a CAGR of 14.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.0% and 12.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

Global GMP Cell Banking Services Market - Key Trends and Drivers Summarized

Why Are GMP Cell Banking Services Becoming Crucial in Biopharmaceutical Development and Therapeutics?

GMP cell banking services are becoming essential in the biopharmaceutical industry due to the increasing demand for safe, reliable, and high-quality cell lines for therapeutic development. But why are these services so critical today? GMP (Good Manufacturing Practice) cell banking refers to the creation, storage, and maintenance of cell lines under stringent regulatory and quality control standards. These services ensure that cell lines used in the production of biologics, vaccines, gene therapies, and other therapeutics are free from contamination and retain their integrity over time.

In biopharmaceutical development, the use of cell lines is foundational, particularly in the production of monoclonal antibodies, recombinant proteins, and viral vectors for gene therapy. The process of GMP cell banking involves generating master cell banks (MCBs) and working cell banks (WCBs), which are critical for scaling up the production of biologics. Cell lines are preserved under controlled conditions to maintain their viability and genetic stability, ensuring consistency across multiple production batches. Given the regulatory requirements from agencies such as the FDA and EMA, GMP cell banking is indispensable for meeting compliance standards, ensuring the safety and efficacy of therapeutics, and accelerating their path to market. As the biopharmaceutical industry continues to expand with the rise of biologics and personalized medicine, GMP cell banking services are integral to the safe and reliable production of these advanced therapies.

How Are Technological Advancements Enhancing GMP Cell Banking Services?

Technological advancements are playing a significant role in improving the efficiency, safety, and scalability of GMP cell banking services, making it easier for biopharmaceutical companies to maintain high-quality cell lines for therapeutic production. One of the most impactful advancements is the use of automated cell culture systems, which allow for more precise and reproducible cell banking processes. Automation reduces human error and ensures that cell banks are prepared, monitored, and maintained under optimal conditions, minimizing the risk of contamination or variation in cell line characteristics. This is particularly important in large-scale production environments where consistency is critical.

Cryopreservation techniques have also advanced, allowing for the long-term storage of cell lines without compromising their viability or functionality. Improvements in cryoprotectant formulations and freezing protocols have enhanced the ability to store cells at ultra-low temperatures, reducing the risk of ice crystal formation, which can damage cells. These advancements ensure that cell banks remain viable for extended periods, often decades, while preserving their genetic and phenotypic integrity. This is vital for the reproducibility of biologic manufacturing processes, especially when a consistent supply of high-quality cells is required over the course of several years.

The integration of advanced analytics and quality control technologies into GMP cell banking is also revolutionizing the field. Techniques such as next-generation sequencing (NGS), flow cytometry, and digital PCR (dPCR) are being used to characterize cell lines more thoroughly, ensuring that they are free from contaminants like mycoplasma or viruses and that their genetic identity is preserved. These advanced analytics allow for better monitoring of cell bank quality, providing biopharmaceutical companies with detailed information on the health and stability of their cell lines. This level of control is particularly important in the development of advanced therapies like gene and cell therapies, where even minor variations in the cell line can impact the efficacy and safety of the final product.

Additionally, advancements in documentation and data management systems are improving the traceability and regulatory compliance of GMP cell banking services. Modern software platforms allow for the comprehensive documentation of all processes involved in cell banking, from initial characterization to cryopreservation and storage. These systems make it easier for biopharmaceutical companies to track the history of their cell banks, ensuring compliance with regulatory guidelines and facilitating audits by agencies like the FDA or EMA. The ability to demonstrate full control and traceability over cell lines is essential for gaining regulatory approval for biologics and ensuring the long-term success of therapeutic products.

Why Are GMP Cell Banking Services Critical for Ensuring the Safety, Stability, and Scalability of Biologics?

GMP cell banking services are critical for ensuring the safety, stability, and scalability of biologics because they provide a controlled and compliant system for producing consistent, high-quality therapeutic products. In the production of biologics-such as monoclonal antibodies, vaccines, and gene therapies-cell lines are used as the biological factories that produce these complex molecules. Ensuring that these cell lines are free from contamination, genetically stable, and capable of reproducible performance is essential for the successful development and manufacturing of biologics.

Safety is a primary concern in the biopharmaceutical industry, and GMP cell banking services are crucial for mitigating risks related to contamination and variability in cell lines. Contaminants such as bacteria, viruses, and mycoplasma can compromise the safety and efficacy of biologics, potentially leading to adverse patient outcomes or regulatory recalls. GMP cell banking ensures that cell lines are thoroughly tested and validated for the absence of contaminants before being used in the production of therapeutic products. This rigorous testing and monitoring process reduces the risk of contamination and ensures that biopharmaceutical companies can produce safe, reliable biologics for patients.

Stability is another key benefit provided by GMP cell banking. Biologics must be produced consistently over time, often across multiple manufacturing batches, to meet the demands of clinical trials and commercialization. The establishment of master and working cell banks guarantees that the cell lines used in production remain genetically stable and functionally reliable over time. By cryopreserving the master cell bank (MCB) and creating working cell banks (WCB) from this source, biopharmaceutical companies can ensure that their production processes remain consistent, even years after the initial creation of the cell line. This stability is essential for maintaining the quality and efficacy of biologics throughout their lifecycle.

Scalability is also critical in the commercial production of biologics, where the ability to produce large quantities of therapeutic products is essential for meeting market demand. GMP cell banking services enable the large-scale production of biologics by providing a consistent and scalable supply of high-quality cell lines. The creation of working cell banks from a master cell bank ensures that biopharmaceutical companies have a ready supply of cells that can be expanded and used for manufacturing at any scale. This scalability is particularly important in the development of advanced therapies like gene and cell therapies, where the ability to produce consistent batches of cells at large volumes is key to commercial success.

Additionally, GMP cell banking services support regulatory compliance by adhering to strict quality control and documentation standards. Biopharmaceutical companies must demonstrate to regulatory agencies that their cell lines are safe, stable, and well-characterized before they can bring biologics to market. GMP-compliant cell banks provide the necessary documentation and traceability to meet these regulatory requirements, ensuring that biopharmaceutical companies can navigate the approval process efficiently. Without GMP cell banking, it would be challenging to meet the rigorous standards set by regulatory agencies, putting the development and commercialization of biologics at risk.

What Factors Are Driving the Growth of the GMP Cell Banking Services Market?

Several key factors are driving the growth of the GMP cell banking services market, including the increasing demand for biologics and advanced therapies, the rise of personalized medicine, the expansion of clinical trials globally, and the stringent regulatory environment governing biopharmaceutical development. First, the growing demand for biologics-such as monoclonal antibodies, vaccines, and gene therapies-is a major driver of the GMP cell banking market. As biopharmaceutical companies expand their pipelines to include more biologics, there is an increasing need for reliable and compliant cell banking services to support the production of these complex therapeutics. Cell banks are critical for ensuring the consistency and quality of biologics throughout their development, clinical trials, and commercial production.

Second, the rise of personalized medicine is contributing to the demand for GMP cell banking services. Personalized therapies, such as CAR-T cell therapies and gene-editing treatments, often require the use of patient-specific or genetically engineered cell lines. GMP cell banking services play a key role in maintaining the quality and safety of these cell lines, ensuring that they remain stable and viable for use in personalized treatments. As the biopharmaceutical industry continues to shift toward individualized therapies, the need for high-quality GMP cell banks will grow to support the production of patient-specific biologics.

The expansion of clinical trials globally is another factor driving the growth of the GMP cell banking market. As clinical trials become more international and involve larger patient populations, biopharmaceutical companies must scale up their production capabilities to meet the increased demand for therapeutic products. GMP cell banking services provide the infrastructure needed to produce consistent, high-quality biologics at scale, ensuring that clinical trials can proceed without interruptions due to supply shortages or quality issues. Additionally, as more advanced therapies enter clinical trials, the need for well-characterized, GMP-compliant cell banks is becoming even more critical.

The stringent regulatory environment governing biopharmaceutical development is also fueling the demand for GMP cell banking services. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require biopharmaceutical companies to demonstrate that their cell lines meet strict quality standards before they can be used in the production of biologics. GMP cell banking ensures that these cell lines are thoroughly tested, documented, and compliant with regulatory guidelines, reducing the risk of delays in the approval process. As regulatory requirements for biologics become more complex, the demand for GMP-compliant cell banking services is expected to grow.

In conclusion, the growth of the GMP cell banking services market is driven by the increasing demand for biologics and advanced therapies, the rise of personalized medicine, the expansion of global clinical trials, and the stringent regulatory environment governing biopharmaceutical development. As the biopharmaceutical industry continues to evolve and prioritize the production of high-quality, safe, and effective therapeutics, GMP cell banking services will play a central role in supporting the development and commercialization of these life-saving treatments.

SCOPE OF STUDY:

The report analyzes the GMP Cell Banking Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cell Type (Mammalian, Microbial, Yeast, Insect, Avian, Other Cell Types); End-Use (Biopharmaceutical Companies, Contract Manufacturing Organizations)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Austrianova Singapore Pte Ltd.
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • Goodwin Biotechnology, Inc.
  • Lonza Group AG
  • Merck KgaA
  • Paragon Bioservices, Inc.
  • SGS India Pvt. Ltd.
  • ViruSure GmbH
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • GMP Cell Banking Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for GMP Cell Banking Services Driven by Growth in Biopharmaceuticals
    • Innovations in Cell Preservation and Storage Techniques Enhance Service Offerings
    • Growth in Outsourcing of Cell Banking Services by Pharmaceutical Companies
    • Market Opportunities in Emerging Regions with Expanding Healthcare Sectors
    • Consumer Trends Toward Advanced Therapeutic Medicinal Products (ATMPs)
    • Future Directions: Integration of Blockchain for Traceability in Cell Banking
    • Innovations in Cryopreservation Technologies for Enhanced Cell Recovery
    • Impact of Biobanking on the Development of Regenerative Medicine
    • Expansion of Cell Banks for Rare Disease Research and Therapy Development
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World 6-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Contract Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 4: World 6-Year Perspective for Contract Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World 6-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Microbial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World 6-Year Perspective for Microbial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Yeast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 10: World 6-Year Perspective for Yeast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Insect by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World 6-Year Perspective for Insect by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Avian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World 6-Year Perspective for Avian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 15: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 16: World 6-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 17: World GMP Cell Banking Services Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for GMP Cell Banking Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for GMP Cell Banking Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • CANADA
    • TABLE 24: Canada Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Canada 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • JAPAN
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 28: Japan Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Japan 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 30: Japan Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • CHINA
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: China 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 34: China Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • EUROPE
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 36: Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Europe 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for GMP Cell Banking Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • FRANCE
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 42: France Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: France 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 44: France Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • GERMANY
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 46: Germany Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Germany 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 48: Germany Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Italy 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 52: Italy Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 54: UK Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: UK 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 56: UK Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Rest of Europe 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • GMP Cell Banking Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 66: Rest of World Recent Past, Current & Future Analysis for GMP Cell Banking Services by End-Use - Biopharmaceutical Companies and Contract Manufacturing Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Rest of World 6-Year Perspective for GMP Cell Banking Services by End-Use - Percentage Breakdown of Value Sales for Biopharmaceutical Companies and Contract Manufacturing Organizations for the Years 2025 & 2030
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for GMP Cell Banking Services by Cell Type - Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of World 6-Year Perspective for GMP Cell Banking Services by Cell Type - Percentage Breakdown of Value Sales for Mammalian, Microbial, Yeast, Insect, Avian and Other Cell Types for the Years 2025 & 2030

IV. COMPETITION